BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 1536783)

  • 1. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen.
    Oikarinen A; Autio P; Vuori J; Väänänen K; Risteli L; Kiistala U; Risteli J
    Br J Dermatol; 1992 Feb; 126(2):172-8. PubMed ID: 1536783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum markers of collagen synthesis and degradation in skin diseases. Altered levels in diseases with systemic manifestation and during systemic glucocorticoid treatment.
    Autio P; Risteli J; Kiistala U; Risteli L; Karvonen J; Oikarinen A
    Arch Dermatol Res; 1993; 285(6):322-7. PubMed ID: 8215582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
    Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; DiNero G
    Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
    Lammi L; Kinnula V; Lähde S; Risteli J; Pääkkö P; Lakari E; Ryhänen L
    Eur Respir J; 1997 Dec; 10(12):2725-30. PubMed ID: 9493651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus.
    Villa-Manzano AI; Gamez-Nava JI; Salazar-Paramo M; Valera-Gonzalez IC; Garcia-Gonzalez A; Garcia-Gonzalez G; Morales-Romero J; Lopez-Olivo A; Galvan-Ramirez LM; Ruiz-Ruvalcaba R; Cardona-Muñoz EG; Gonzalez-Lopez L
    Rheumatol Int; 2006 Jun; 26(8):712-6. PubMed ID: 16231121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of systemic isotretinoin on serum markers of collagen synthesis and degradation.
    Autio P; Risteli J; Palatsi R; Väänänen K; Vuori J; Risteli L; Oikarinen A
    Acta Derm Venereol; 1993 Apr; 73(2):108-12. PubMed ID: 8103253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis.
    Heickendorff L; Zachariae H; Bjerring P; Halkier-Sørensen L; Søndergaard K
    J Am Acad Dermatol; 1995 Apr; 32(4):584-8. PubMed ID: 7896946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.
    Lin DY; Chu CM; Sheen IS; Liaw YF
    Dig Dis Sci; 1995 Jan; 40(1):21-7. PubMed ID: 7821112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen in children with growth retardation.
    Cinaz P; Hasanoglu E; Gökçora N; Dogukan S; Demir A
    Mater Med Pol; 1994; 26(2):55-8. PubMed ID: 7745984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
    López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
    Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.
    Terzolo M; Piovesan A; Osella G; Pia A; Reimondo G; Pozzi C; Raucci C; Torta M; Paccotti P; Angeli A
    Calcif Tissue Int; 1993 Mar; 52(3):188-91. PubMed ID: 8481830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and tissue levels of collagen types I and III markers in patients with abdominal aortic aneurysms.
    Treska V; Topolcan O
    Int Angiol; 2000 Mar; 19(1):64-8. PubMed ID: 10853688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of meningeal fibrosis after subarachnoid haemorrhage by assaying procollagen propeptides in cerebrospinal fluid.
    Sajanti J; Majamaa K
    J Neurol Neurosurg Psychiatry; 1999 Aug; 67(2):185-8. PubMed ID: 10406986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.
    Kjeldsen J; Schaffalitzky de Muckadell OB; Junker P
    Gut; 1995 Dec; 37(6):805-10. PubMed ID: 8537052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism.
    Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Artuso V; Di Virgilio R; Conte N
    Horm Metab Res; 1994 Jul; 26(7):334-7. PubMed ID: 7959610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoids inhibit the synthesis rate of type III collagen, but do not affect the hepatic clearance of its aminoterminal propeptide (PIIINP).
    Hansen M; Stoltenberg M; Høst NB; Boesby S; Lorenzen I; Bentsen KD
    Scand J Clin Lab Invest; 1995 Oct; 55(6):543-8. PubMed ID: 8571085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum type I collagen propeptide and severity of alcoholic liver disease.
    Niemelä O; Blake JE; Orrego H
    Alcohol Clin Exp Res; 1992 Dec; 16(6):1064-7. PubMed ID: 1471760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collagen synthesis in intact skin is suppressed during wound healing.
    Ihlberg L; Haukipuro K; Risteli L; Oikarinen A; Kairaluoma MI; Risteli J
    Ann Surg; 1993 Apr; 217(4):397-403. PubMed ID: 8466311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.
    Conti A; Sartorio A; Ferrero S; Ferrario S; Ambrosi B
    J Endocrinol Invest; 1996 Feb; 19(2):127-30. PubMed ID: 8778165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.